Are you Dr. Wood?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 51 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
451 Junction Rd
Madison, WI 53717Phone+1 608-265-0700Fax+1 608-265-7759
Summary
- Dr. Gary Wood, MD is a board certified dermatologist in Madison, Wisconsin. He is currently licensed to practice medicine in Wisconsin, Ohio, and California. He is affiliated with William S. Middleton Memorial Veterans' Hospital and is a Professor of Dermatology at University Wisc.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityResidency, Dermatology, 1983 - 1985- Stanford Health Care-Sponsored Stanford UniversityResidency, Pathology-Anatomic and Clinical, 1981 - 1982
Stanford Health CareInternship, Transitional Year, 1979 - 1980
University of Illinois College of MedicineClass of 1979
Certifications & Licensure
OH State Medical License 1989 - 2025
WI State Medical License 2001 - 2025
CA State Medical License 1981 - 2024- American Board of Dermatology Dermatology
- American Board of Dermatology Dermatopathology
- American Board of Pathology Anatomic Pathology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2004-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Fellow (FAAD) American Academy of Dermatology
- Join now to see all
Clinical Trials
- Forodesine in the Treatment of Cutaneous T-Cell Lymphoma Start of enrollment: 2007 Jul 01
Publications & Presentations
PubMed
- 284 citationsEORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary...Werner Kempf, Katrin Pfaltz, Maarten H. Vermeer, Antonio Cozzio, Pablo L. Ortiz-Romero
Blood. 2011-10-13 - 191 citationsApoptosis and melanoma: molecular mechanisms.Mahmoud R. Hussein, Anna Haemel, Gary S. Wood
The Journal of Pathology. 2003-03-01 - 125 citationsTopical Chemotherapy in Cutaneous T-cell Lymphoma: Positive Results of a Randomized, Controlled, Multicenter Trial Testing the Efficacy and Safety of a Novel Mechloret...Stuart R. Lessin, Madeleine Duvic, Joan Guitart, Amit G. Pandya, Bruce Strober
JAMA Dermatology. 2013-01-01
Press Mentions
Total Skin Electron Radiation Used to Treat Rare CancerMarch 2nd, 2017
Grant Support
- Phase II Rhil-12 In MF With Cross-Over To Phase I IL-2 Administered With IL-12National Center For Research Resources2004–2006
- Translational Research &Mentoring In Cutaneous LymphomaNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2000–2003
- Phase I Trial Of 06 Benzylguanine &Bcnu In Cutaneous T Cell LymphomaNational Center For Research Resources2000–2002
- Translational Research &Mentoring In Cutaneous LymphomaNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1999–2000
- Core--Cellular And Molecular MorphologyNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1994–1998
- Murine Model Of Cutaneous Lymphoid HyperplasiaNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1997
- Treatment Of CTCL With O6 Benzylguanine/BcnuNational Cancer Institute1997
- HTLV-I Mycosis Fungoides/Sezary SyndromeNational Cancer Institute1994–1996
- Dendritic Cell Leukocyte Common AntigenNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1994–1995
- Analysis Of Dendritic Cell Leukocyte Common AntigenNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1991–1993
Professional Memberships
- Fellow
- Fellow
